



FOR IMMEDIATE RELEASE

Contact:
Susan Brady
Corporate Communications
617.621.8304
sbrady@ironwoodpharma.com

IRONWOOD PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2010 INVESTOR UPDATE CALL

CAMBRIDGE, Mass., August 2, 2010 — [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) today announced it will issue its second quarter 2010 investor update after the U.S. financial markets close on Thursday, August 5, 2010. In connection with this announcement, Ironwood will host a conference call and webcast at 5:30 p.m. Eastern Time on the same day. Individuals interested in participating in the call should dial (877) 312-5420 (U.S. and Canada) or (970) 315-0261 (international) using conference ID number 91630665. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required. The call will be available for replay via telephone starting August 5, 2010 at 8:30 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on August 19, 2010. To listen to the replay, dial (800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international) using conference ID number 91630665. An archived version of the event will be available on Ironwood's website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.

SOURCE: Ironwood Pharmaceuticals, Inc.